RT Journal Article
SR Electronic
T1 Azithromycin alters spatial and temporal dynamics of airway microbiota in idiopathic pulmonary fibrosis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.09.14.22279909
DO 10.1101/2022.09.14.22279909
A1 Gijs, Pieter-Jan
A1 Daccord, Cécile
A1 Bernasconi, Eric
A1 Brutsche, Martin
A1 Clarenbach, Christian
A1 Hostettler, Katrin
A1 Guler, Sabina A.
A1 Mercier, Louis
A1 Ubags, Niki
A1 Funke-Chambour, Manuela
A1 Garnier, Christophe von
YR 2022
UL http://medrxiv.org/content/early/2022/09/15/2022.09.14.22279909.abstract
AB Background High bacterial burden in lung microbiota predicts progression of idiopathic pulmonary fibrosis (IPF). Azithromycin is a macrolide antibiotic known to alter the lung microbiota in several chronic pulmonary diseases and observational studies have shown a positive effect of azithromycin on mortality and hospitalization rate in IPF. However, the effect of AZT on lung microbiota in IPF remain unknown.Methods We sought to determine the impact of a three-month course of azithromycin on lung microbiota in IPF. We assessed sputum and oropharyngeal swab specimens from 24 adults with IPF included in a randomized controlled cross-over trial of a thrice-weekly 500 mg oral azithromycin. 16S rRNA sequencing and quantitative polymerase chain reaction (qPCR) were performed to assess bacterial communities. Antibiotic resistance genes (ARG) were assessed using real-time qPCR.Results Azithromycin significantly decreased community diversity with a stronger and more persistent effect in lower airways. During treatment, turnover of airway microbiota decreased in upper and lower airways, resulting in greater similarity between microbiota of the two sites persisting one month after macrolide cessation.Patients with increased expression of ARG had a lower bacterial load and an enrichment of the genus Streptococcus. In contrast, patients without increased in ARG expression had a higher bacterial load and an enrichment in Prevotella.Conclusions We observed that AZT caused sustained changes in the diversity and composition of the upper and lower airway microbiota in IPF, with effects on the temporal and spatial dynamics between the two sites.Competing Interest StatementAll authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: no support from any organisation for the submitted work; CC has received honorariums from GSK, Novartis, Vifor, Boehringer, Astra Zeneca, Sanofi and does consulting for Daiichi Sankyo, MFC has received honorariums for MSD, Novartis and received consulting fees from Boehringer Ingelheim and Daiichi SankyoClinical TrialNCT02173145Funding StatementThis study was supported by a fund from the Lung Association of the Canton de Vaud (Ligue Pulmonaire Vaudoise, LPV), Switzerland, awarded to CD and EB. The initial interventional which allowed sample availability was supported by the Research Fund of the Swiss Lung Association (Lungenliga Schweiz), awarded to MFC. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval was obtained by the Swiss Ethics Committee,Bern (KEK 002/14)before the start of the study, and all patients provided written informed consent before inclusionI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors https://github.com/chuvpne/dada2-pipeline. https://github.com/CHUVpulmonology/Airway_microbiota-Lung_fibrosis-Azithromycin